Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

November

7

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

DENVER–(BUSINESS WIRE)–Nov. 7, 2024– TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), a leader...

31

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

Call Scheduled for Thursday, November 14, 2024, at 9:00am ET DENVER–(BUSINESS WIRE)–Oct. 31, 2024– TriSalus Life Sciences® Inc.,...

15

TriSalus Reports Q2 2024 Financial Results and Business Update

DENVER–(BUSINESS WIRE)–Aug. 15, 2024– TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating novel...

3

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting

– Hepatic arterial infusion (HAI) of nelitolimod has been well tolerated and associated with encouraging...

27

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

– New safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced...

6

TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics

Devlin Brings Significant Expertise in Commercialization, Sales and Marketing DENVER–(BUSINESS WIRE)–Sep. 6, 2023– TriSalus...

20

TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies

Data further substantiates potential to significantly improve immunotherapy outcomes for patients with liver and...

12

TriSalus Life Sciences Opens Its First Research Laboratory on Lifespan Health System’s Campus

Immunotherapeutic collaboration will advance efforts to develop new treatment options for patients with liver...

7

TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pressure-Enabled Drug Delivery in Uveal Melanoma Liver Metastases

Study to evaluate the delivery of SD-101, an investigational TLR9 agonist, in combination with...

9

TriSalus Life Sciences Receives Expanded Reimbursement Authorization from CMS for TriNav Infusion System

Transitional Pass Through Payment (TPT) Facilitates Patient Access to New and Innovative Products That...

22

TriSalus Life Sciences Appoints Trevor McCaw as Chief Commercial Officer

Experienced commercial leader solidifies Company’s management team as it integrates novel therapies with innovative...

29

TriSalus Life Sciences Appoints Steven Katz, M.D., Chief Medical Officer

Renowned surgeon, clinician, and researcher to advance work to combine novel immuno-oncology therapies with...

Recent developments

News

November

7

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

October

31

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

August

15

TriSalus Reports Q2 2024 Financial Results and Business Update

June

3

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting

March

27

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

September

6

TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics

November

20

TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies

April

12

TriSalus Life Sciences Opens Its First Research Laboratory on Lifespan Health System’s Campus

September

7

TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pressure-Enabled Drug Delivery in Uveal Melanoma Liver Metastases

February

9

TriSalus Life Sciences Receives Expanded Reimbursement Authorization from CMS for TriNav Infusion System

October

22

TriSalus Life Sciences Appoints Trevor McCaw as Chief Commercial Officer

September

29

TriSalus Life Sciences Appoints Steven Katz, M.D., Chief Medical Officer